OMass Therapeutics Ltd has appointed two executives in the US and one in the UK to support the advancement of the company’s pipeline of small molecule therapeutics in rare diseases and immunological conditions. The executives in the US are Steve Griffen, vice president of clinical development and Angela Hecyk, director of clinical operations, while in the UK, Stuart Hadley has been named senior director of chemistry manufacture and controls. Dr Griffen, an endocrinologist with 25 years’ experience, previously was vice president, clinical development at MBX Biosciences and the medical lead for integrated care at Sanofi. He holds an MA in endocrinology from the University of California, Berkeley and a medical doctorate from the Medical College of Wisconsin, both US. OMass uses structural mass spectrometry to discover new medicines and has selected a clinical candidate targeting the melanocortin-2 (MC2) receptor, a G-protein coupled receptor (GPCR) for the adrenocorticotropic hormone.
OMass announced the appointment on 1 October 2024.
Copyright 2024 Evernow Publishing Ltd